TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03005652

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness weekly courses for 8 weeks
Description: The mindfulness intervention combines intensive training in mindfulness and compassion meditations, light movement and yoga activities, and psycho-educational components to promote nonjudgmental awareness of present moment experiences.
Study: NCT02643719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abortive Medication (Naproxen and Sumatriptan)
Description: All participants will receive abortive medication for acute treatment of their migraine. Preferred medications are Naproxen (500mg) and Sumatriptan (100mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abortive Medication (Naproxen and Sumatriptan)
Description: All participants will receive abortive medication for acute treatment of their migraine. Preferred medications are Naproxen (500mg) and Sumatriptan (100mg)
Study: NCT02305381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.
Study: NCT03164941

Intervention type: PROCEDURE
Intervention: Selective Laser Trabeculoplasty
Description: Laser treatment for glaucoma.

Intervention type: PROCEDURE
Intervention: Selective Laser Trabeculoplasty
Description: Laser treatment for glaucoma.
Study: NCT02381743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 2 intervention daily SMS bullet point
Description: Group 2 subjects receive a daily SMS bullet point, summarizing a key clinical point pertinent to the CBPA's daily work.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 3 intervention daily SMS bullet point
Description: Group 3 subjects receive a c phrased as a multiple choice question. The content mirrors that of group 2, but is presented as a question to render it interactive
Study: NCT02341287

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Warming hydrogel glove
Description: Subjects wore the warming hydrogel glove in either the first or second two-week period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Warming hydrogel glove
Description: Subjects wore the warming hydrogel glove in either the first or second two-week period.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non-thermal glove
Description: Subjects wore the non-thermal glove in either the first or second two-week period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-thermal glove
Description: Subjects wore the non-thermal glove in either the first or second two-week period.
Study: NCT03615521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hotpack
Description: Hotpack applied 20 minutes for knee 3 session for 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hotpack
Description: Hotpack applied 20 minutes for knee 3 session for 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hotpack
Description: Hotpack applied 20 minutes for knee 3 session for 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound applied 10 minutes for knee 3 session for 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound applied 10 minutes for knee 3 session for 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound applied 10 minutes for knee 3 session for 6 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combine Exercise
Description: Proprioceptive Neuromusculer Facilitation Technique İnclude eccentric and concentric contractions 3 session for 6 week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated Contraction Exercise
Description: Proprioceptive Neuromusculer Facilitation Technique include concentric contractions 3 session for 6 week

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standart Exercise Therapy
Description: Quadriceps, hamstring and hip muscle strength exercise. Hamstring stretch exercise.~3 session for 6 week
Study: NCT03841123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Counseling
Description: The intervention will consist of an individualized, face-to-face, 20 to 30 minute counseling session to mothers by trained health workers who will address healthy eating practices during the first two years of life. A printed, colorful and illustrated material will be used to assist mothers in appropriate food choices, mainly to avoid the introduction of sugar and ultra-processed foods. In addition, they will receive a booklet which addresses the Ten Steps of Healthy Feeding for children from Birth to Two years of life. The research team will focus on Step2: Do not give added sugar or foods with added sugar, and Step8:Do not offer ultra-processed foods as candies and soft drinks. To reinforce the intervention, mothers will receive telephone calls up to the infant reach six months.
Study: NCT04033172

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib Plus Fulvestrant
Description: Pyrotinib: 400 mg/d, q.d., p.o. A course of treatment need 28 days. Fulvestrant: 500 mg/m2 q.d. i.m. A course of treatment need 28 day. First course needs extra dose of fulvestrant 500 mg/m2 q.d. i.m. on day 15.
Study: NCT00823420

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prematuration culture
Description: The aneuploidy rate and the developmental potential of embryos obtained from PDE3 inhibitor-treated oocytes (a prolonged IVM (PMC)) in comparison to conventional IVM will be analysed. It is intended to assess the nuclear and cytogenetic constitution of the obtained embryos.
Study: NCT00553202

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV or orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic bone marrow transplantation
Description: allogeneic bone marrow transplantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic hematopoietic SCT
Study: NCT00077636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 400mg po bid for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copegus
Description: 400mg po bid for 24 weeks
Study: NCT03005652

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education weekly courses for 8 weeks
Description: The health education intervention is group-based programme has been developed and validated in an SCD population. Each session of the course covers different subjects, which include self-management, problem-solving, sleep, stress, exercise, managing medicines and memory, communicating with healthcare professionals, eating, and planning for the future.
Study: NCT00077636

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc weekly for 16 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 180 micrograms sc weekly for 24 weeks
Study: NCT01923896

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Behavioral intervention targeting severe feeding disorders involves the combination of escape extinction and antecedent manipulation of food presentation to lessen the aversive quality of the meal. This allows treatment to address the consequences maintaining food refusal in the least restrictive environment while ameliorating possible side effects associated with extinction procedures.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention
Description: Behavioral intervention targeting severe feeding disorders involves the combination of escape extinction and antecedent manipulation of food presentation to lessen the aversive quality of the meal. This allows treatment to address the consequences maintaining food refusal in the least restrictive environment while ameliorating possible side effects associated with extinction procedures.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-cycloserine (DCS)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: lactose powder
Study: NCT02679521

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ESWT
Description: Radial extracorporeal shock wave therapy (rESWT) was performed by the principal investigator with a Swiss DolorClast device (EMS Electro Medical Systems Corporation; Dallas, Texas, USA).~The Swiss DolorClast device obtained Pre-Market Approval (PMA) by FDA as Class III orthopedic lithotripsy device to treat heel pain associated with chronic proximal plantar fasciitis on May 8, 2007 (PMA # P050004), and was re-classified as Class III Generator, Shock Wave, For Pain Relief (Product Code NBN) in the Spring 2009. The present study started on October 3, 2007.~Each patient received two sessions of rESWT one week apart, with 2,000 impulses per session (air pressure of the device set at 3.5 bar; impulses applied with the 15 mm applicator at frequency of 8 Hz).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo treatment was performed identically as rESWT but with a clasp on the heel that prevented transmission of the impulses from the applicator to the skin at the treatment site.
Study: NCT02714868

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project TEAM
Description: Project TEAM is a manualized, group-based intervention designed to be co-facilitated by an experienced leader with a disability (disability advocate) and a licensed service provider (such as an occupational therapist, social worker, or educator). Project TEAM includes eight group sessions and two experiential learning field trips for each participant. Weekly phone calls with peer mentors with disabilities support achievement of each participant's personal activity goal.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Matched Comparison
Description: Participants set goal to try a new activity in the community
Study: NCT02040272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: (Extended) pleurectomy decortication
Study: NCT04389333

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-contact magnetically-controlled capsule endoscopy
Description: The novel non-contact magnetically-controlled capsule endoscopy (MCE) system (Ankon Technologies, Wuhan, China) (Figure 1) added a remote control workstation and an audio-visual exchange system to the original well-establish MCE system, which consisted of a robotic magnetic arm, a workstation (currently bypassed) and a capsule endoscope.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-contact magnetically-controlled capsule endoscopy
Description: The novel non-contact magnetically-controlled capsule endoscopy (MCE) system (Ankon Technologies, Wuhan, China) (Figure 1) added a remote control workstation and an audio-visual exchange system to the original well-establish MCE system, which consisted of a robotic magnetic arm, a workstation (currently bypassed) and a capsule endoscope.
Study: NCT02010697

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messages targeting nonsmokers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Messages targeting smokers
Study: NCT01623843

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Arthroscopic Lavage
Description: Lavage: inflammation debris caused from continual friction in the hip is washed out.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopic Osteochondroplasty
Description: Osteochondroplasty: reshaping the hip ball and socket (osteoplasty or rim trimming).
Study: NCT04123106

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ESP block
Description: ESP block bilaterally performed at the level of the surgical site prior to surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wound infiltration
Description: Wound infiltration performed at the surgical site at the end of surgery.
Study: NCT04498689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Patients firstly receive camrelizumab 200 mg per time (iv, no less than 20 minutes and no more than 60 minutes, rinse time included) on Day 1 and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence, unacceptable toxicity, death or begin a novel therapeutic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab paclitaxel
Description: Patients secondly receive nab-paclitaxel 100 mg/m2 (iv, at least 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence, unacceptable toxicity, death or begin a novel therapeutic.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Injection
Description: At last, patients receive gemcitabine 1000 mg/m2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks until the disease recurrence, unacceptable toxicity, death or begin a novel therapeutic.
Study: NCT02562638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-fasting
Description: Clear fluids up to 1hour pre-procedure and fasting for solids for up to 4 hours
Study: NCT04310709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib/Nivolumab
Description: Combination of regorafenib and nivolumab
Study: NCT01457586

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Blood transfusion
Description: Blood transfusion in perioperative period.

Intervention type: BIOLOGICAL
Group type: NO_INTERVENTION
Intervention: No blood transfusion
Description: No transfusion in the perioperative period.
Study: NCT04212208

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IV cannulation
Description: IV cannulation in the preoperative period

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IV cannulation
Description: IV cannulation in the preoperative period
Study: NCT04070690

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Concentration of dialysate bicarbonate
Description: Adjust the dialysate bicarbonate concentration

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Concentration of dialysate bicarbonate
Description: Adjust the dialysate bicarbonate concentration
Study: NCT03809468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: phone call follow up
Description: instead of a clinic visit, patients will be randomized to a phone call
Study: NCT01772745

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SILS cholecystectomy
Description: Single incision laparoscopic cholecystectomy will be performed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TPCL cholecystectomy
Description: Three port laparoscopic cholecystectomy will br performed
Study: NCT03854370

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baby shampoo
Description: baby shampoo will be used to prepare the surgical site prior to incision

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Betadine
Description: Betadine (Povidone- iodine) will be used to prepare the surgical site prior to incision

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Peridex
Description: Peridex (Chlorhexidine) will be used to prepare the surgical site prior to incision

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TechniCare
Description: TechniCare (chloroxynel) will be used to prepare the surgical site prior to incision
Study: NCT00786331

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 of a 21 days cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed plus carboplatin
Description: Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 and Carboplatin AUC 5 i.v. over approximately 30 minutes on day 1 (beginning approximately 30 minutes after the end of the pemetrexed infusion) of a 21 days cycle
Study: NCT01500187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vanish Varnish
Description: 5% sodium fluoride varnish with tricalcium phosphate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pediagel
Description: 1.23% Acidulated Phosphate Fluoride Gel
Study: NCT00648622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol Tablets 12.5 mg
Description: 12.5mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coreg® Tablets 12.5 mg
Description: 12.5mg, single dose fed
Study: NCT03138252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Study: NCT00682370

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: intravenous infusion, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heme arginate
Description: intravenous infusion, single dose~0.3 mg/kg heme arginate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heme arginate
Description: intravenous infusion, single dose~1 mg/kg heme arginate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: heme arginate
Description: intravenous infusion, single dose~3 mg/kg heme arginate
Study: NCT03122743

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of serum samples

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02029989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucose and lipids
Description: Point-of-care (POCT) screening for diabetes and dyslipidemia.~Glucose and Lipids

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glucose and lipids
Description: Point-of-care (POCT) screening for diabetes and dyslipidemia.~Glucose and Lipids

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glycosylated Hemoglobin A1c
Description: Point-of-care (POCT) screening for diabetes~Glycosylated Hemoglobin A1c

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glycosylated Hemoglobin A1c
Description: Point-of-care (POCT) screening for diabetes~Glycosylated Hemoglobin A1c

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Pressure and Heart Rate
Description: Point-of-care (POCT) screening for hypertension~Blood Pressure and Heart Rate

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Pressure and Heart Rate
Description: Point-of-care (POCT) screening for hypertension~Blood Pressure and Heart Rate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Body mass index
Description: Height and weight measurement used to calculate BMI = Mass(kg)/(height (m))squared

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Body mass index
Description: Height and weight measurement used to calculate BMI = Mass(kg)/(height (m))squared

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Waist and Hip circumference
Description: Measurement for Central Obesity~Waist and Hip circumference

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Waist and Hip circumference
Description: Measurement for Central Obesity~Waist and Hip circumference

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Comprehensive Medication Management
Description: Defined at http://www.pcpcc.org/guide/patient-health-through-medication-management
Study: NCT01187498

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral training
Description: Comprehensive behavioral training program using delayed voiding, urge suppression techniques, pelvic floor muscle training, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin chloride, extended-release
Description: Individually titrated, extended-release oxybutynin chloride, initiated at 10 mg, fluid management handout, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.
Study: NCT00006251

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO
Study: NCT00965003

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: Standard of Care
Study: NCT00006251

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic PBSC transplant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: donor lymphocytes
Description: Undergo DLI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic PBSC transplant

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies